铁缺乏对房颤患者预后的影响:伴或不伴慢性心力衰竭
丹麦全国性队列研究纳入10 834例房颤患者,按心衰状态分层,评估四种铁缺乏定义与全因死亡、心血管死亡及全因住院的关联。中位随访31个月,TSAT<20%或血清铁≤13 µmol/L与死亡风险增加相关,且不依赖心衰状态;ESC标准或铁蛋白<100 ng/mL未显示与死亡相关。
要点
- TSAT<20%或血清铁≤13 µmol/L与房颤患者全因及心血管死亡风险增加相关,无论是否合并心衰。
- ESC指南定义或铁蛋白<100 ng/mL的铁缺乏与死亡无关,但与心衰患者全因住院风险增加相关。
- 不同铁缺乏定义患病率差异大(36.2%–62.7%),临床风险分层应优先考虑TSAT和血清铁。
核心结论
- TSAT<20%或血清铁≤13 µmol/L定义的铁缺乏与房颤患者死亡风险增加相关,且不依赖心衰状态,提示这些标准可用于风险分层。
研究设计与样本
- 丹麦全国性队列研究,纳入2008至2019年间接受铁代谢检查的10 834例房颤患者,按心衰状态分层,采用Cox回归模型校正混杂因素。
主要发现
- 铁缺乏患病率随定义不同波动于36.2%至62.7%。
- 中位随访31个月,TSAT<20%与心衰患者全因死亡HR 1.25(95%CI 1.14–1.37)、心血管死亡HR 1.31(95%CI 1.14–1.49)相关;无心衰患者全因死亡HR 1.39(95%CI 1.18–1.64)、心血管死亡HR 1.54(95%CI 1.18–2.00)相关。
- 血清铁≤13 µmol/L与心衰患者全因死亡HR 1.44(95%CI 1.31–1.58)、心血管死亡HR 1.42(95%CI 1.24–1.63)相关;无心衰患者全因死亡HR 1.67(95%CI 1.41–1.97)、心血管死亡HR 1.46(95%CI 1.13–1.89)相关。
- ESC指南定义或铁蛋白<100 ng/mL与死亡无关,但与心衰患者全因住院风险增加相关(HR 1.15,95%CI 1.08–1.23;HR 1.16,95%CI 1.09–1.23)。
关键数值与推荐
- 铁缺乏定义:ESC指南标准、铁蛋白<100 ng/mL、TSAT<20%、血清铁≤13 µmol/L。
- TSAT<20%和血清铁≤13 µmol/L与死亡风险增加相关;ESC标准或铁蛋白<100 ng/mL仅与心衰患者住院风险增加相关。
临床怎么用
- 对房颤患者评估铁缺乏时,可优先采用TSAT<20%或血清铁≤13 µmol/L识别死亡高风险人群,无论是否合并心衰。
- 铁蛋白<100 ng/mL或ESC标准虽与死亡无关,但可用于识别心衰患者住院风险增加。
局限性
- 观察性队列设计,无法确立因果关系。
- 铁缺乏定义未统一,不同标准患病率差异大,可能影响结果解读。
- 仅纳入接受铁代谢检查的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iron deficiency (ID) is common in patients with atrial fibrillation/flutter (AF), but its prognostic implications and optimal diagnostic criteria, particularly in those with and without heart failure (HF), remain unclear. This study assessed the associations between different ID definitions and clinical outcomes in patients with AF. METHODS: This Danish nationwide cohort study included 10 834 patients with AF who underwent iron studies between 2008 and 2019, stratified by HF status. ID was defined using four criteria: European Society of Cardiology (ESC) guidelines, ferritin <100 ng/mL, transferrin saturation (TSAT) <20% and serum iron ≤13 µmol/L. Associations between ID definitions and all-cause mortality, cardiovascular mortality and all-cause hospitalisation were evaluated using Cox regression models, adjusted for confounders. RESULTS: Prevalence of ID varied substantially across definitions, ranging from 36.2% to 62.7%. Over a median follow-up of 31 months, TSAT <20% was associated with increased all-cause and cardiovascular mortality in both HF (HR 1.25, 95% CI 1.14 to 1.37 and HR 1.31, 95% CI 1.14 to 1.49, respectively) and patients without HF (HR 1.39, 95% CI 1.18 to 1.64 and HR 1.54, 95% CI 1.18 to 2.00, respectively). Similarly, serum iron ≤13 µmol/L was associated with higher all-cause and cardiovascular mortality in HF (HR 1.44, 95% CI 1.31 to 1.58 and HR 1.42, 95% CI 1.24 to 1.63, respectively) and patients without HF (HR 1.67, 95% CI 1.41 to 1.97 and HR 1.46, 95% CI 1.13 to 1.89, respectively). ID defined by ESC guidelines or ferritin <100 ng/mL was not associated with mortality in either group but was linked to higher all-cause hospitalisation in patients with HF (HR 1.15, 95% CI 1.08 to 1.23 and HR 1.16, 95% CI 1.09 to 1.23, respectively). CONCLUSIONS: ID defined by TSAT <20% or serum iron ≤13 µmol/L is associated with increased mortality in patients with AF, irrespective of HF status, highlighting these criteria as clinically relevant for risk stratification.
引用
- Mohamed, Christensen, Mohammad, et al. Prognostic implications of iron deficiency in patients with atrial fibrillation, with and without chronic heart failure. Heart. 2025. PMID: 39922691. doi:10.1136/heartjnl-2024-325244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。